Embodiments of the disclosure encompass methods and compositions related to the ability of RNA to enhance therapeutic activity of fibroblasts. In some embodiments, administration of double stranded RNA is performed through providing polyinosinicpolycytidylic acid (poly (I:C)) or a derivative thereof at a concentration sufficient to induce therapeutic properties and/or to augment therapeutic properties onto said fibroblasts. In one embodiment, enhanced therapeutic activity comprises augmentation of fibroblast migratory activity; efficacy for angiogenesis; efficacy for immune modulation; differentiation ability; production of one or more trophic factors; and/or the ability to resist apoptosis.

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

The present disclosure provides compositions and methods for assaying the effectiveness of a potential therapeutic agent for treatment of an activated GαQ mutant cancer (e.g., melanoma or angiosarcoma) or an activated GαQ mutant melanocytic malignancy (e.g., Portwine stain or Sturge-Weber syndrome). Also disclosed herein are methods for treating an activated GαQ mutant cancer (e.g., melanoma or angiosarcoma) or an activated GαQ mutant melanocytic malignancy (e.g., Portwine stain or Sturge-Weber syndrome) in a subject in need thereof.

The present disclosure provides compositions and methods for assaying the effectiveness of a potential therapeutic agent for treatment of an activated GαQ mutant cancer (e.g., melanoma or angiosarcoma) or an activated GαQ mutant melanocytic malignancy (e.g., Portwine stain or Sturge-Weber syndrome). Also disclosed herein are methods for treating an activated GαQ mutant cancer (e.g., melanoma or angiosarcoma) or an activated GαQ mutant melanocytic malignancy (e.g., Portwine stain or Sturge-Weber syndrome) in a subject in need thereof.

The present invention describes a process for obtaining extracellular matrix from the skin of tilapia (Oreochromis niloticus) comprising the steps of chemical and enzymatic decellularization, detoxification, chemical disinfection, crosslinking, bleaching, dehydration and sterilization by gamma radiation, more specifically the steps comprised by each of said procedures and use of the extracellular matrix for treating ruptured of tissues, dermatitises, acute, chronic and traumatic lesions, battlefield wounds, necrotic wounds, lacerations, abrasions, bruises and other lesions and conditions. The present invention falls within the fields of pharmacy, medicine and veterinary medicine, dentistry, chemistry, tissue engineering, molecular biology and biotechnology.

A Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like contain an extract from inflamed tissues inoculated with vaccinia virus. The extract from inflamed tissues inoculated with vaccinia virus promotes differentiation of Schwann cells and regeneration of a peripheral nerve. Therefore, a preparation containing the extract from inflamed tissues inoculated with vaccinia virus is useful as a Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like.

A Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like contain an extract from inflamed tissues inoculated with vaccinia virus. The extract from inflamed tissues inoculated with vaccinia virus promotes differentiation of Schwann cells and regeneration of a peripheral nerve. Therefore, a preparation containing the extract from inflamed tissues inoculated with vaccinia virus is useful as a Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like.

The invention in relates in part to a method for rejuvenating hair follicles, the method comprising the steps of: (1) obtaining androgen non-inhibited cells from hair follicle tissue; (2) culturing the androgen non-inhibited cells to produce an expanded population of androgen-non-inhibited cells; and (3) implanting the expanded population of androgen non-inhibited cells proximal to miniaturised and/or miniaturising hair follicles.

The invention in relates in part to a method for rejuvenating hair follicles, the method comprising the steps of: (1) obtaining androgen non-inhibited cells from hair follicle tissue; (2) culturing the androgen non-inhibited cells to produce an expanded population of androgen-non-inhibited cells; and (3) implanting the expanded population of androgen non-inhibited cells proximal to miniaturised and/or miniaturising hair follicles.